Cargando…

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

Therapy-related leukemia (TRL) has been reported to occur after treatment with alkylating agents and/or topoisomerase II inhibitors. Oxaliplatin (OXP) is used as a key drug for the treatment of colorectal cancer (CRC). Cisplatin and carboplatin have been linked with TRL, but the involvement of OXP i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Akari, Takada, Kohichi, Horiguchi, Hiroto, Sato, Tsutomu, Iyama, Satoshi, Murase, Kazuyuki, Kamihara, Yusuke, Ono, Kaoru, Tatekoshi, Ayumi, Hayashi, Tsuyoshi, Miyanishi, Koji, Sato, Yasushi, Furuhata, Tomohisa, Kobune, Masayoshi, Takimoto, Rishu, Hirata, Koichi, Kato, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049016/
https://www.ncbi.nlm.nih.gov/pubmed/24932174
http://dx.doi.org/10.1159/000363100
_version_ 1782480580292640768
author Hashimoto, Akari
Takada, Kohichi
Horiguchi, Hiroto
Sato, Tsutomu
Iyama, Satoshi
Murase, Kazuyuki
Kamihara, Yusuke
Ono, Kaoru
Tatekoshi, Ayumi
Hayashi, Tsuyoshi
Miyanishi, Koji
Sato, Yasushi
Furuhata, Tomohisa
Kobune, Masayoshi
Takimoto, Rishu
Hirata, Koichi
Kato, Junji
author_facet Hashimoto, Akari
Takada, Kohichi
Horiguchi, Hiroto
Sato, Tsutomu
Iyama, Satoshi
Murase, Kazuyuki
Kamihara, Yusuke
Ono, Kaoru
Tatekoshi, Ayumi
Hayashi, Tsuyoshi
Miyanishi, Koji
Sato, Yasushi
Furuhata, Tomohisa
Kobune, Masayoshi
Takimoto, Rishu
Hirata, Koichi
Kato, Junji
author_sort Hashimoto, Akari
collection PubMed
description Therapy-related leukemia (TRL) has been reported to occur after treatment with alkylating agents and/or topoisomerase II inhibitors. Oxaliplatin (OXP) is used as a key drug for the treatment of colorectal cancer (CRC). Cisplatin and carboplatin have been linked with TRL, but the involvement of OXP is questionable. A 74-year-old male was diagnosed with peritoneal metastasis from CRC in July 2011. The patient received nine cycles of 5-fluorouracil (5-FU), leucovorin (LV), and OXP (mFOLFOX-6 regimen) and three cycles of 5-FU and LV only, resulting in a clinical complete response. However, recurrence of CRC was detected by CT within 3 months after the last course of chemotherapy. In April 2013, laboratory tests showed pancytopenia and 15% blast cells. A bone marrow examination revealed multilineage dysplasia and 20.4% myeloblasts. Cytogenetic analysis indicated a complex karyotype that included chromosome 5 and 7 abnormalities. The patient was diagnosed with TRL and treated with a combination of azacitidine (AZA) and cetuximab (Cmab) for both cancers. AZA might be useful in TRL when a patient needs to be treated simultaneously for more than one primary cancer because of its low toxicity. Moreover, Cmab is an effective therapeutic tool in TRL patients with metastatic CRC with the wild-type K-ras gene.
format Online
Article
Text
id pubmed-4049016
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-40490162014-06-13 Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer Hashimoto, Akari Takada, Kohichi Horiguchi, Hiroto Sato, Tsutomu Iyama, Satoshi Murase, Kazuyuki Kamihara, Yusuke Ono, Kaoru Tatekoshi, Ayumi Hayashi, Tsuyoshi Miyanishi, Koji Sato, Yasushi Furuhata, Tomohisa Kobune, Masayoshi Takimoto, Rishu Hirata, Koichi Kato, Junji Case Rep Oncol Published online: May, 2014 Therapy-related leukemia (TRL) has been reported to occur after treatment with alkylating agents and/or topoisomerase II inhibitors. Oxaliplatin (OXP) is used as a key drug for the treatment of colorectal cancer (CRC). Cisplatin and carboplatin have been linked with TRL, but the involvement of OXP is questionable. A 74-year-old male was diagnosed with peritoneal metastasis from CRC in July 2011. The patient received nine cycles of 5-fluorouracil (5-FU), leucovorin (LV), and OXP (mFOLFOX-6 regimen) and three cycles of 5-FU and LV only, resulting in a clinical complete response. However, recurrence of CRC was detected by CT within 3 months after the last course of chemotherapy. In April 2013, laboratory tests showed pancytopenia and 15% blast cells. A bone marrow examination revealed multilineage dysplasia and 20.4% myeloblasts. Cytogenetic analysis indicated a complex karyotype that included chromosome 5 and 7 abnormalities. The patient was diagnosed with TRL and treated with a combination of azacitidine (AZA) and cetuximab (Cmab) for both cancers. AZA might be useful in TRL when a patient needs to be treated simultaneously for more than one primary cancer because of its low toxicity. Moreover, Cmab is an effective therapeutic tool in TRL patients with metastatic CRC with the wild-type K-ras gene. S. Karger AG 2014-05-17 /pmc/articles/PMC4049016/ /pubmed/24932174 http://dx.doi.org/10.1159/000363100 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: May, 2014
Hashimoto, Akari
Takada, Kohichi
Horiguchi, Hiroto
Sato, Tsutomu
Iyama, Satoshi
Murase, Kazuyuki
Kamihara, Yusuke
Ono, Kaoru
Tatekoshi, Ayumi
Hayashi, Tsuyoshi
Miyanishi, Koji
Sato, Yasushi
Furuhata, Tomohisa
Kobune, Masayoshi
Takimoto, Rishu
Hirata, Koichi
Kato, Junji
Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title_full Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title_fullStr Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title_full_unstemmed Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title_short Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
title_sort combination chemotherapy of azacitidine and cetuximab for therapy-related acute myeloid leukemia following oxaliplatin for metastatic colorectal cancer
topic Published online: May, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049016/
https://www.ncbi.nlm.nih.gov/pubmed/24932174
http://dx.doi.org/10.1159/000363100
work_keys_str_mv AT hashimotoakari combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT takadakohichi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT horiguchihiroto combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT satotsutomu combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT iyamasatoshi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT murasekazuyuki combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT kamiharayusuke combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT onokaoru combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT tatekoshiayumi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT hayashitsuyoshi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT miyanishikoji combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT satoyasushi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT furuhatatomohisa combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT kobunemasayoshi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT takimotorishu combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT hiratakoichi combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer
AT katojunji combinationchemotherapyofazacitidineandcetuximabfortherapyrelatedacutemyeloidleukemiafollowingoxaliplatinformetastaticcolorectalcancer